Drug intelligence / Profile preview

Baracle

Development stage: Phase 4
Lead developer: Dong-A ST
Modality: Small Molecules
Administration: Oral

Overview

Baracle is an antiviral medication developed by Dong-A ST Co., Ltd. It is a generic version of entecavir, a guanosine nucleoside analog, primarily indicated for the treatment of chronic hepatitis B virus (HBV) infection. Entecavir functions by inhibiting the HBV polymerase, thereby interfering with the viral replication process at multiple stages, including base priming, reverse transcription of the negative strand of messenger RNA, and synthesis of the positive strand of HBV DNA. It is administered orally in tablet form.

Brand names: Baracle Tab.

Targets

HBV Pol (Hepatitis B virus polymerase)

Beyond the preview

Go deeper on Baracle.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Baracle.

Explore the full profile